Global Kinase Inhibitor in Autoimmune Diseases Market Insights and Market Forecast – 2030

May 27 19:54 2021
Global Kinase Inhibitor in Autoimmune Diseases Market Insights and Market Forecast - 2030

DelveInsight Business Research LLP
DelveInsight’s ‘Global Kinase Inhibitor in Autoimmune Diseases Market Insights and Market Forecast – 2030’ report delivers an in-depth understanding of the market trends of Global Kinase Inhibitor in Autoimmune Diseases across the globe.

What is Global Kinase Inhibitor in Autoimmune Diseases?

Immunological disorders are diseases or conditions caused by a dysfunction of the immune system and include allergy, asthma, autoimmune diseases, autoinflammatory syndromes, and immunological deficiency syndromes.

Global Kinase Inhibitor in Autoimmune Diseases Market Outlook

According to DelveInsight, Global Kinase Inhibitors in Autoimmune Diseases Market to continue on growth trajectory with 19.17% CAGR during the study period (2018-2030).

Monoclonal antibodies (biologics) impede the action of pathogenic cytokines that emerged two decades ago and have become broadly valuable for autoimmune and inflammatory diseases. Lately, agents that simultaneously hinder various pathogenic cytokines via inhibition of the downstream Janus kinase (JAK)-signal transducer and activator of transcription pathway have come up and are becoming increasingly imperative. These small-molecule inhibitors, collectively known as JAK inhibitors, are the US Food and Drug Administration sanctioned in a few autoimmune/inflammatory disorders and assessed in many others. First-generation jakinibs stop multiple JAKs and therefore hinder the actions of a tremendous variety of cytokines, and various pan-JAK inhibitors continue to be developed.

Xeljanz/Xeljanz XR is a JAK inhibitor that is formulated with the citrate salt of tofacitinib. JAKs are intracellular enzymes that transmit signals from cytokine or growth factor-receptor interactions on the cellular membrane to impact cellular processes of hematopoiesis and immune cell function. Within the signalling pathway, JAKs phosphorylate and activate signal transducers and activators of transcription (STATs), which modulate intracellular activity, including gene expression. Tofacitinib modulates the signalling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. It is approved for Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, and Polyarticular course juvenile idiopathic arthritis (pcJIA).

Which biotechnological companies involved in the development of Global Kinase Inhibitor in Autoimmune Diseases therapies?

 

Global Kinase Inhibitor in Autoimmune Diseases Emerging Therapies Along with Key Players

  • Ritlecitinib: Pfizer
  • PF-06650833/Tofacitinib: Pfizer
  • SHR0302: Reistone Biopharma
  • Abrocitinib: Pfizer
  • Ruxolitinib: Incyte Corporation
  • Branebrutinib: Bristol Myers Squibb
  • GLPG3970: Galapagos NV
  • ATI-450: Aclaris Therapeutics
  • TAS5315: Taiho Pharma
  • OST-122: Oncostellae
  • Remibrutinib: Novartis Pharmaceuticals
  • ATI-1777: Aclaris Therapeutics
  • Izencitinib: Theravance Biopharma and Janssen (Johnson & Johnson)
  • PF-06826647: Pfizer
  • Deucravacitinib (BMS-986165): BMS
  • PF-06700841 (Brepocitinib): Pfizer
  • Belumosudil: Kadmon Pharmaceuticals
  • Elsubrutinib: AbbVie

And several others.

Lastly, Global Kinase Inhibitor in Autoimmune Diseases Market Growth will observe traction in market size due to patient compliance, increased research and development, increased prevalence of autoimmune and inflammatory diseases, and next-generation Jakinibs nevertheless Global Kinase Inhibitor in Autoimmune Diseases Market Barriers such as variable efficacy, estimating exact patient pool, and existing therapies will hinder the market size.

Scope of the Report

  • The report covers the descriptive overview of Global Kinase Inhibitor in Autoimmune Diseases, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Global Kinase Inhibitor in Autoimmune Diseases treatment across the globe.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Global Kinase Inhibitor in Autoimmune Diseases is provided, along with the assessment of new therapies, which will impact the current treatment landscape.
  • A detailed review of the Global Kinase Inhibitor in Autoimmune Diseases market, historical and forecasted, is included in the report, covering drug outreach in the globe.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the worldwide Global Kinase Inhibitor in the Autoimmune Diseases market.

 

Table of contents 

1.  Key Insights

2.  Report Introduction

3.  GKIAD Market Overview at a Glance

3.1. Market Share (%) Distribution of GKIAD in 2018

3.2. Market Share (%) Distribution of GKIAD in 2030

4.  Executive Summary of Global Kinase Inhibitors in Autoimmune Disease (GKIAD)

5.  Global Kinase Inhibitor in Autoimmune Disorders

5.1. Introduction to Immunological Disorders

5.2. Kinase Inhibitors in Autoimmune Diseases

5.3. Various Immunological Disorders

5.3.1.Rheumatoid Arthritis (RA)

5.3.2.Disease Background and Overview

5.3.2.1. Stages of RA

5.3.2.2. Types of RA

5.3.2.3. Signs and Symptoms of RA

5.3.2.4. Risk Factors and Causes of RA

5.3.2.5. Pathogenesis of RA

5.3.3.Current Treatment Practices: RA

5.3.3.1. Medications

5.3.3.2. Supportive Treatment

5.3.3.3. Surgery

5.3.3.4. Treatment Algorithm

5.3.3.5. Guideline of RA

5.3.4.Psoriasis

5.3.5.Disease Background and Overview

5.3.5.1. Causes and Triggers

5.3.5.2. Locations

5.3.5.3. Types of Psoriasis

5.3.5.4. Pathophysiology

5.3.6.Treatment and Management

5.3.6.1. Topicals

5.3.6.2. Phototherapy

5.3.6.3. Systemics

5.3.7.Crohn’s Disease (CD)

5.3.8.Disease Background and Overview

5.3.8.1. Types of CD

5.3.8.2. Classification of CD

5.3.8.3. Signs and Symptoms of CD

5.3.8.4. Risk Factors and Causes of CD

5.3.8.5. Pathophysiology of CD

5.3.9.Current Treatment Practices: CD

5.3.9.1. Treatment Algorithm of CD

5.3.9.2. Drug Therapies

5.3.9.3. Surgery

5.3.9.4. Diet and Nutrition

5.3.9.5. Treatment and Management Guidelines of CD

5.3.10. Ulcerative Colitis (UC):

5.3.11. Disease Background and Overview

5.3.11.1. Types of UC

5.3.11.2. Classification of UC

5.3.11.3. Signs and Symptoms of UC

5.3.11.4. Risk Factors and Causes of UC

5.3.11.5. Pathophysiology of UC

5.3.11.6. Severity Scoring System

5.3.12. Current Treatment Practices: UC

5.3.12.1. Treatment Algorithm of UC

5.3.12.2. Drug Therapies

5.3.12.3. Other therapies

5.3.12.4. Surgery

5.3.12.5. Diet and Nutrition

5.3.12.6. Treatment and Management Guidelines of CD

5.3.13. Psoriatic Arthritis (PsA)

5.3.14. Disease Background and Overview

5.3.14.1. Clinical Manifestations

5.3.14.2. Classification

5.3.14.3. Risk Factors

5.3.14.4. Pathogenesis of PSA

5.3.15. Treatment and Management

5.3.15.1. ACR/NPF Recommendations for Psoriatic arthritis

5.3.15.2. Summary of differences in recommendations

5.3.15.3. EULAR Recommendations

5.3.16. Other Immunological disorder

5.3.17. Sjogren Syndrome

5.3.18. Atopic Dermatitis

6.  Marketed Drugs

6.1. Key cross Competition

6.2. Xeljanz (Tofacitinib): Pfizer

6.2.1.Product Description

6.2.2.Regulatory Milestones for Rheumatoid Arthritis:

6.2.3.Regulatory Milestones for Psoriatic Arthritis:

6.2.4.Regulatory Milestones for Ulcerative Colitis

6.2.5.Regulatory Milestones for Polyarticular Course juvenile idiopathic arthritis

6.2.6.Safety and Efficacy of Xeljanz for Rheumatoid Arthritis

6.2.7.Safety and Efficacy of Xeljanz for Psoriatic Arthritis

6.2.8.Safety and Efficacy of Xeljanz for Polyarticular Course juvenile idiopathic arthritis

6.2.9.Side effects of Xeljanz

6.2.10. Product Profile

6.3. Olumiant: Eli Lily and Incyte Corporation

6.3.1.Product Description

6.3.2.Regulatory Milestone for rheumatoid arthritis

6.3.3.Regulatory Milestone for Atopic Dermatitis

6.3.4.Safety and Efficacy for Rheumatoid arthritis

6.3.5.Safety and Efficacy for Atopic Dermatitis

6.3.6.Side effects of Olumiant

6.3.7.Product Profile

6.4. RINVOQ: AbbVie

6.4.1.Product Description

6.4.2.Regulatory Milestone

6.4.3.Safety and Efficacy for RA

6.4.4.Safety and Efficacy for PsA

6.4.5.Safety and Efficacy for Ankylosing spondylitis

6.4.6.Side effects of RINVOQ

6.4.7.Other developmental activities

6.4.8.Clinical Development

6.4.9.Clinical trial information

6.4.10. Safety and Efficacy

6.4.11. Product Profile

6.5. Jyseleca: Gilead Sciences

6.5.1.Product Description

6.5.2.Regulatory Milestone

6.5.3.Safety and Efficacy

6.5.4.Side Effects of Jyseleca

6.5.5.Other development activities

6.5.6.Clinical Development

6.5.7.Clinical trial information

6.5.8.Safety and Efficacy

6.5.9.Product Profile

6.6. Smyraf: Astellas Pharma

6.6.1.Product Description

6.6.2.Regulatory Milestone

6.6.3.Safety and Efficacy

6.6.4.Side Effects of Smyraf

6.6.5.Product Profile

6.7. Corectim: Japan Tobacco and Torii Pharmaceutical

6.7.1.Product Description

6.7.2.Regulatory Milestone

6.7.3.Safety and Efficacy

6.7.4.Side Effects of CORECTIM Ointment 0.5%

6.7.5.Product Profile

7.  Emerging Therapies

7.1. Key Cross Competition

7.2. Ritlecitinib: Pfizer

7.2.1.Drug Description

7.2.2.Clinical Development

7.2.3.Clinical trial information

7.2.4.Safety and Efficacy

7.2.5.Product Profile

7.3. Ritlecitinib/PF-06650833/ Tofacitinib: Pfizer

7.3.1.Drug Description

7.3.2.Clinical Development

7.3.3.Clinical trial information

7.3.4.Product Profile

7.4. SHR0302: Reistone Biopharma

7.4.1.Drug Description

7.4.2.Other development Activities

7.4.3.Clinical Development

7.4.4.Clinical trial information

7.4.5.Safety and Efficacy

7.4.6.Product Profile

7.5. Abrocitinib: Pfizer

7.5.1.Drug Description

7.5.2.Other Development Activities

7.5.3.Clinical Development

7.5.4.Clinical trial information

7.5.5.Safety and Efficacy

7.5.6.Product Profile

7.6. Ruxolitinib: Incyte Corporation

7.6.1.Drug Description

7.6.2.Other Development Activities

7.6.3.Clinical Development

7.6.4.Clinical trial information

7.6.5.Safety and Efficacy

7.6.6.Product Profile

7.7. Branebrutinib: Bristol Myers Squibb

7.7.1.Drug Description

7.7.2.Other Development Activities

7.7.3.Clinical Development

7.7.4.Clinical trial information

7.7.5.Safety and Efficacy

7.7.6.Product Profile

7.8. GLPG3970: Galapagos NV

7.8.1.Drug Description

7.8.2.Other Development Activity

7.8.3.Clinical Development

7.8.4.Clinical trial information

7.8.5.Product Profile

7.9. ATI-450: Aclaris Therapeutics

7.9.1.Drug Description

7.9.2.Other Developmental Activities

7.9.3.Clinical Development

7.9.4.Clinical trial information

7.9.5.Safety and Efficacy

7.9.6.Product Profile

7.10. TAS5315: Tahio Pharma

7.10.1. Drug Description

7.10.2. Clinical Development

7.10.3. Clinical trial information

7.10.4. Product Profile

7.11. OST-122: Oncostellae

7.11.1. Drug Description

7.11.2. Clinical Development

7.11.3. Clinical trial information

7.11.4. Product Profile

7.12. Remibrutinib: Novartis Pharmaceuticals

7.12.1. Drug Description

7.12.2. Clinical Development

7.12.3. Clinical trial information

7.12.4. Product Profile

7.13. ATI-1777: Aclaris Therapeutics

7.13.1. Drug Description

7.13.2. Other Developmental Activities

7.13.3. Clinical Development

7.13.4. Clinical trial information

7.13.5. Product Profile

7.14. Izencitinib: Theravance Biopharma and Janssen (Johnson & Johnson)

7.14.1. Drug Description

7.14.2. Other Developmental Activities

7.14.3. Clinical Development

7.14.4. Clinical trial information

7.14.5. Product Profile

7.15. PF-06826647: Pfizer

7.15.1. Drug Description

7.15.2. Clinical Development

7.15.3. Clinical Trials Information

7.15.4. Safety and Efficacy

7.15.5. Product Profile

7.16. Deucravacitinib (BMS-986165): BMS

7.16.1. Drug Description

7.16.2. Clinical Development

7.16.3. Clinical Trials Information

7.16.4. Safety and Efficacy

7.16.5. Product Profile

7.17. PF-06700841 (Brepocitinib): Pfizer

7.17.1. Drug Description

7.17.2. Clinical Development

7.17.3. Clinical Trials Information

7.17.4. Safety and Efficacy

7.17.5. Product Profile

7.18. Belumosudil: Kadmon Pharmaceuticals

7.18.1. Drug Description

7.18.2. Other Clinical Development

7.18.3. Clinical Development

7.18.4. Clinical Trials Information

7.18.5. Safety and Efficacy

7.18.6. Product Profile

7.19. Elsubrutinib: AbbVie

7.19.1. Drug Description

7.19.2. Clinical Development

7.19.3. Clinical Trials Information

7.19.4. Product Profile

8.  Global Kinase Inhibitors in Autoimmune Disease: Market Analysis

8.1. Key Findings

8.2. Market Size of GKIAD

8.3. Market Outlook

8.4. Corectim: Japan Tobacco and Torii Pharmaceutical

8.5. The United States

8.5.1.Total Market Size of GKIAD in the United States

8.5.2.Market Size of GKIAD by Therapies in the United States

8.6. EU-5

8.6.1.Total Market Size of GKIAD in EU5

8.6.2.Market Size of GKIAD by Therapies in EU5

8.7. Japan

8.7.1.Total Market size of GKIAD in Japan

8.7.2.Market Size of GKIAD by Therapies in Japan

8.8. Rest of World (RoW)

8.8.1.Total Market size of GKIAD in RoW

8.8.2.Market Size of GKIAD by Therapies in Japan

9.  Key Opinion Leaders

10. Market Drivers

11. Market Barrier

12. SWOT Analysis

13. Unmet Needs

14. Appendix

14.1. Bibliography

14.2. Report Methodology

15. DelveInsight Capabilities

16. Disclaimer

17. About DelveInsight

 

Request sample pages for more information on Global Kinase Inhibitor in Autoimmune Diseases Market Size 

 

Media Contact
Company Name: DelveInsight
Contact Person: DelveInsight
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/